Every material Form 8-K Krystal Biotech filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Krystal Biotech reported third-quarter 2024 net product revenue of $83.8 million, up from $8.6 million a year earlier, driven by VYJUVEK sales. Net income fell to $27.2 million, or $0.91 per diluted share, from $80.7 million, or $2.79 per diluted share, a year earlier; that period included a $100 million gain on the sale of a priority review voucher, and this quarter included a $12.5 million litigation settlement charge. The company also set full-year 2024 non-GAAP R&D and SG&A expense guidance of $115 million to $125 million.
Q3 2024 net product revenue was $83.8 million versus $8.6 million in Q3 2023; gross margin for VYJUVEK was 92% for the quarter.
Q3 2024 net income was $27.2 million, or $0.91 per diluted share, compared with $80.7 million, or $2.79 per diluted share, in Q3 2023.
Q3 2024 included a $12.5 million litigation settlement expense and $100 million gain from a priority review voucher sale was recorded in Q3 2023.
Cash, cash equivalents and investments totaled $694.2 million as of September 30, 2024; full-year 2024 non-GAAP R&D and SG&A guidance is $115 million to $125 million.
Krystal Biotech reported second-quarter 2024 product revenue of $70.3 million from VYJUVEK, up 55.3% from the first quarter, and net income of $15.6 million ($0.53 per diluted share), compared with a net loss of $33.2 million a year earlier. Results include a $12.5 million litigation settlement charge, and the company kept its 2024 R&D and SG&A expense guidance of $150 million to $175 million (non-GAAP, excluding stock-based compensation) unchanged.
Q2 2024 product revenue, net: $70.3 million, up 55.3% from Q1 2024; gross margin 91%
Q2 2024 net income: $15.6 million, or $0.53 per diluted share, versus a net loss of $33.2 million in Q2 2023
Q2 2024 included a $12.5 million litigation settlement expense
Cash, cash equivalents and investments: $628.9 million as of June 30, 2024; 2024 R&D and SG&A guidance unchanged
Krystal Biotech reported its first quarter 2024 results, its first product revenue after the May 2023 FDA approval of VYJUVEK, with net product revenue of $45.3 million and net income of $0.9 million, or $0.03 per share. A year earlier the company posted a net loss of $45.3 million, or $1.76 per share. The company said it continues to expect $150 million to $175 million of non-GAAP R&D and SG&A expense for 2024.
Net product revenue was $45.3 million for the quarter ended March 31, 2024, with gross margin of 95%.
Net income was $0.9 million, or $0.03 per share, compared with a net loss of $45.3 million, or $1.76 per share, in the first quarter of 2023.
Cash, cash equivalents and investments totaled $622.3 million on March 31, 2024.
The company continues to anticipate $150 million to $175 million of 2024 non-GAAP combined R&D and SG&A expense, excluding stock-based compensation.
Krystal Biotech reported fourth-quarter and full-year 2023 results, with net product revenue of $42.1 million in the quarter and $50.7 million for the year from VYJUVEK, which was approved in May 2023. The company posted net income of $8.7 million for the quarter versus a $32.1 million loss a year earlier, and $10.9 million for the year, which includes a $100.0 million gain from selling a Priority Review Voucher. The company also gave 2024 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million.
Q4 2023 net product revenue was $42.1 million, versus no product revenue in Q4 2022.
Q4 2023 net income was $8.7 million ($0.31 per basic share), compared with a loss of $32.1 million in Q4 2022.
Full-year 2023 net income was $10.9 million, including a $100.0 million gain from the sale of a Priority Review Voucher.
2024 non-GAAP combined R&D and SG&A expense guidance is $150.0 million to $175.0 million; cash and investments were $594.1 million at December 31, 2023.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Krystal Biotech filing is on SEC EDGAR ↗. 8-K briefs of other companies →